Is CyberArk Stock a Buy, Sell or Hold?
CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has…
Buy
53
HIMS Quote, Financials, Valuation and Earnings
Last price:
$34.79
Seasonality move
:
2.28%
Day range:
$31.88 - $35.20
52-week range:
$11.20 - $72.98
Dividend yield:
0%
P/E ratio:
64.35x
P/S ratio:
5.57x
P/B ratio:
16.19x
Volume:
45.4M
Avg. volume:
31.5M
1-year change:
107.71%
Market cap:
$7.7B
Revenue:
$1.5B
EPS (TTM):
$0.54
Analysts' Opinion
-
Consensus RatingHims & Hers Health has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 7 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $44.16, Hims & Hers Health has an estimated upside of 27.09% from its current price of $34.75.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 100% downside risk from its current price of $34.75.
Fair Value
-
According to the consensus of 12 analysts, Hims & Hers Health has 27.09% upside to fair value with a price target of $44.16 per share.
HIMS vs. S&P 500
-
Over the past 5 trading days, Hims & Hers Health has overperformed the S&P 500 by 4.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Hims & Hers Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Hims & Hers Health has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Hims & Hers Health reported revenues of $481.1M.
Earnings Growth
-
Hims & Hers Health has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Hims & Hers Health reported earnings per share of $0.11.
Enterprise value:
7.4B
EV / Invested capital:
--
Price / LTM sales:
5.57x
EV / EBIT:
119.87x
EV / Revenue:
5.03x
PEG ratio (5yr expected):
--
EV / Free cash flow:
37.41x
Price / Operating cash flow:
41.48x
Enterprise value / EBITDA:
93.93x
Gross Profit (TTM):
$1.2B
Return On Assets:
23.52%
Net Income Margin (TTM):
8.54%
Return On Equity:
32.03%
Return On Invested Capital:
32.03%
Operating Margin:
3.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $526.9M | $872M | $1.5B | $246.6M | $481.1M | |
| Gross Profit | $408.7M | $714.9M | $1.2B | $204.1M | $369.5M | |
| Operating Income | -$68.7M | -$29.5M | $61.9M | -$400K | $18.6M | |
| EBITDA | -$61.2M | -$19.9M | $79M | $2.3M | $24.7M | |
| Diluted EPS | -$0.32 | -$0.11 | $0.54 | $0.01 | $0.11 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $113.1M | $269.9M | $216.6M | $265.1M | $395.8M | |
| Total Assets | $118.7M | $420.6M | $366.3M | $441.2M | $707.5M | |
| Current Liabilities | $15.2M | $79.2M | $47.9M | $88.5M | $221.4M | |
| Total Liabilities | $265.6M | $86M | $54.6M | $97.2M | $230.8M | |
| Total Equity | -$146.9M | $334.6M | $311.7M | $344M | $476.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$26.5M | $73.5M | $251.1M | $22M | $86.4M | |
| Cash From Investing | $34.7M | -$12.1M | -$19M | $20.7M | -$17.2M | |
| Cash From Financing | -$33.1M | -$11.5M | -$107.8M | -$4M | -$13.7M | |
| Free Cash Flow | -$33.8M | $47M | $198.3M | $10.8M | $59.5M | |
HIMS
Sector
Market Cap
$7.7B
$39.2M
Price % of 52-Week High
47.62%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
1.56%
-0.81%
1-Year Price Total Return
107.71%
-38.63%
Beta (5-Year)
1.368
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$33.29
200-day SMA
Buy
Level
$25.58
Bollinger Bands (100)
Buy
Level
22.29 - 41.87
Chaikin Money Flow
Buy
Level
56.7M
20-day SMA
Sell
Level
$38.86
Relative Strength Index (RSI14)
Sell
Level
45.45
ADX Line
Sell
Level
17.8
Williams %R
Neutral
Level
-66.5474
50-day SMA
Sell
Level
$37.86
MACD (12, 26)
Sell
Level
-2.43
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
41.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (16.0727)
Buy
CA Score
(Annual)
Level (2.0165)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-2.3941)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Stock Forecast FAQ
In the current month, HIMS has received 4 Buy ratings 7 Hold ratings, and 1 Sell ratings. The HIMS average analyst price target in the past 3 months is $44.16.
-
Where Will Hims & Hers Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Hims & Hers Health share price will rise to $44.16 per share over the next 12 months.
-
What Do Analysts Say About Hims & Hers Health?
Analysts are divided on their view about Hims & Hers Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Hims & Hers Health is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Hims & Hers Health's Price Target?
The price target for Hims & Hers Health over the next 1-year time period is forecast to be $44.16 according to 12 Wall Street analysts, 4 of them rate the stock a Buy, 1 rates the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is HIMS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Hims & Hers Health is a Hold. 7 of 12 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HIMS?
You can purchase shares of Hims & Hers Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Hims & Hers Health shares.
-
What Is The Hims & Hers Health Share Price Today?
Hims & Hers Health was last trading at $34.79 per share. This represents the most recent stock quote for Hims & Hers Health. Yesterday, Hims & Hers Health closed at $34.75 per share.
-
How To Buy Hims & Hers Health Stock Online?
In order to purchase Hims & Hers Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Is Palantir a Good Stock to Buy?
Palantir Technologies (PLTR) stock soared to its highest level in…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
